Pure Global AI
NCT06331975Completed

Radiomics and Radiogenomics of Non-small Cell Lung Cancer

Radiomics and Radiogenomics of Non-small Cell Lung Cancer: Relationships of Radiomic Signature With Gene Driver Mutations and Implications for Emerging Therapies
European Institute of OncologyClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Radiomic signature
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
European Institute of Oncology
Location
Milan, Italy
Timeline & enrollment
Phase
N/A
Start date
Jun 12, 2018
End date
Sep 14, 2023
Enrollment
91 participants
Primary outcome

Evaluation of the association between the status of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), Kirsten Rat Sarcoma Virus (KRAS) and nodal status,Evaluation of the association between the status of EGFR, ALK, KRAS and overall survival (OS),Evaluation of the association between the status of EGFR, ALK, KRAS and disease free survival (DFS)

Summary

In this study, the radiomic characteristics and a broad range of genetic aberrations in lung
 adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and
 genetic profiles during targeted therapies in a subset of patients harboring treatable
 mutations. Patients undergoing targeted therapies will also be evaluated for variations in
 genomic profile and radiomic signature during follow-up

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06331975
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06331975 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Completed. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 91 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.